A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Ascending Intravenous Doses of Glofitamab, Administered after Ocrelizumab Pretreatment, in Patients with Multiple Sclerosis

2023-506863-32-00 Protocol BN44083 Human pharmacology (Phase I) - Other Ended

Start 25 Jul 2023 · End 29 Jan 2026 · Status Ended · 2 EU/EEA countries · 3 sites · Protocol BN44083

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 5
Countries 2
Sites 3

Multiple Sclerosis (MS)

Key facts

Sponsor
F. Hoffmann-La Roche AG
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
25 Jul 2023 → 29 Jan 2026
Decision date (initial)
2024-07-11
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-506863-32-00
EudraCT number
2022-001209-33

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Multiple Sclerosis (MS)

VersionLevelCodeTermSystem organ class
20.1 PT 10028245 Multiple sclerosis 100000004852

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

F. Hoffmann-La Roche AG

Sponsor organisation
F. Hoffmann-La Roche AG
Address
Grenzacherstrasse 124
City
Basel
Postcode
4058
Country
Switzerland

Scientific contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Public contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Locations

2 EU/EEA countries · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Croatia Ended 2 2
Czechia Ended 3 1
Rest of world 0

Investigational sites

Croatia

2 sites · Ended
Klinicki bolnicki centar Sestre milosrdnice
Neurology, Vinogradska Cesta 29, Zagreb, Grad Zagreb
KBC Zagreb
Neurology, Ulica Mije Kispatica 12, Zagreb, Grad Zagreb

Czechia

1 site · Ended
Fakultni Nemocnice Hradec Kralove
Neurologie - RS centrum, Sokolska 581, 500 03, Novy Hradec Kralove

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Croatia 2023-07-25 2026-01-19 2023-08-07 2024-03-25
Czechia 2023-08-25 2026-01-28 2023-09-18 2024-03-25

Application history

6 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-06-11 Czechia Acceptable with conditions
2024-07-10
2024-07-11
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-08-21 Czechia Acceptable with conditions
2024-07-10
2024-08-21
3 SUBSTANTIAL MODIFICATION SM-1 2024-09-24 Czechia Acceptable
2024-11-21
2024-11-26
4 NON SUBSTANTIAL MODIFICATION NSM-2 2025-01-30 Acceptable
2024-11-21
2025-01-30
5 SUBSTANTIAL MODIFICATION SM-2 2025-02-17 Czechia Acceptable
2025-04-16
2025-04-16
6 SUBSTANTIAL MODIFICATION SM-3 2025-06-12 Czechia Acceptable
2025-08-29
2025-08-29